Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.



Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering

Philadelphia, USA and Oxford, UK:  Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares (“ADSs”) following its entry into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”) to purchase an aggregate of approximately US$42,000,000 of its ADSs. Adaptimmune sold 7,000,000 ADSs at a price of $6.00 per ADS.

Read the rest of entry »

MGB Biopharma Closes $1 million Financing Round to Finance Manufacturing of MGB-BP-3 for Phase II Study in Clostridium difficile-Associated Disease (CDAD)

Glasgow, Scotland:  MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, announces today that it has raised $1.15 million in a financing round with existing investors.

Read the rest of entry »

Heptares to receive US$12 million milestine payment from AstraZeneca

London, UK: AZD4635 (HTL-1071), a novel adenosine A2A receptor antagonist, reverses adenosine-mediated T-cell suppression and enhances anti-tumour immunity.  New preclinical results presented at AACR Annual Meeting

Read the rest of entry »

Imanova receives £1m award from the MRC to develop early markers of dementia - the MIND-MAPS study

Following a £0.5m Medical Research Council (MRC) grant to implement new Positron Emission Tomography (PET) imaging tracers for mitochondrial dysfunction and synaptic loss, Imanova has been awarded an additional £1m of strategic funding from the MRC for clinical evaluation of this combination of tracers in Alzheimer’s disease and Parkinson’s disease - Stage 1 of the MIND-MAPS (Molecular Imaging of Neurodegenerative Disease – Mitochondria, Associated Proteins & Synapses) programme. Kevin Cox, Imanova’s CEO, commented: “We are delighted to have been awarded strategic funding for the MIND-MAPS programme. We would like to thank the MRC and Dementias Platform UK (DPUK) for supporting the proposal and look forward to engaging more widely with the DPUK Imaging Network.” MIND-MAPS is a pre-competitive consortium between Imanova, AbbVie, the MRC, the Hamamatsu Photonics PET centre, drawing on the therapy area expertise of the DPUK members. The aim of the prog ...

Read the rest of entry »

Minister breaks ground and unveils name for £13 million office & laboratory building at The Oxford Science Park

The minister of state for universities, science, research and innovation, Jo Johnson MP, visited The Oxford Science Park (“the Park”) on Tuesday 4 April 2017 to take part in an official ground-breaking ceremony and reveal the name of the £13 million state of the art new office and laboratory building capable of accommodating 500 people.

Read the rest of entry »

Wickham Labs to Exhibit at Med-Tech Innovation Expo 2017

Wickham Laboratories Ltd is pleased to announce that we will be on Stand 12 at the upcoming Med-Tech Innovation Expo, Ricoh Arena, Coventry, April 26-27.

Med-Tech Innovation Expo 2017 is the UK’s only dedicated medical device conference bringing together industry stakeholders and over 130 companies supplying services from design to post-market surveillance. Alongside the exhibition, there will be a centrepiece conference delivering insights and market intelligence via a wide range of expert speakers.

Read the rest of entry »

Tissue Solutions introduces additions to their extensive range of cellular products

Tissue Solutions introduces additions to their extensive range of cellular products. Available immediately is their portfolio of human iPS-derived cell types which are conveniently already differentiated and ready to use.

Read the rest of entry »

Cresset signs strategic alliance agreement to speed up drug design

British-Chinese three-way agreement brings together expertise and innovation in development of technologies for computational molecule design.

Read the rest of entry »

Neuro-Bio Attracts Over $3 Million In Series A Investment To Develop A New Approach To Alzheimer’s Disease

Oxford, UK Neuro-Bio Ltd, a UK-based early stage biopharmaceutical company focussingon neurodegenerative diseases, today announced it has received Series A funding of $3.2 million from US-based Kairos Ventures to continue developing a diagnostic tool for early detection of Alzheimer’s and to discover new drugs targeting the disease. Neuro-Bio has been pioneering a novel approach to Alzheimer’s disease and related neurodegenerative disorders since 2013. The innovative Neuro-Bio technology is the result of over 40 years of basic research by Baroness Professor Susan Greenfield's group, initially at Oxford University, that points to a previously unidentified mechanism underlying the continuing cycle of cell death that characterises the neurodegenerative process. The company has been exploring whether activation of this brain mechanism could be halted by pharmaceutical intervention and how these changes are reflected in a biomarker present in blood. The new investment will allow Neuro-Bio to develop the biomarker into a diagnostic tool and to make substantive progress towards identifying a lead compound with promising therapeutic potential in Alzheimer’s disease.

Read the rest of entry »

Elasmogen Receives £1.2m In Grant And Equity Investment

Elasmogen Ltd, developer of soloMERTM biologics, today announced that it has received a Biomedical Catalyst Grant from the UK’s innovation agency, Innovate UK and matching investment from Deepbridge Capital and Scottish Investment Bank (the investment arm of Scottish Enterprise) totalling £1.2 M. The funding will be used to develop ELN-21 and ELN-22, the companies’ next generation biologics for topical treatment of ocular disease.

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

Future Blends are looking for an OBN member company who could help them strip solvent from one of their process streams. Initially looking at a 1 tonne scale. If you can help, or know of someone who might be able to then please contact Shane O’Leary at Future Blends. soleary@futureblends.com.

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us, team@obn.org.uk, and we will post.